2026-11-12T12:35:32.000Z · 11 hours ago Piper Sandler upgraded enGene to Overweight on updated LEGEND data
2026-11-12T10:20:19.000Z · 13 hours ago enGene upgraded to Overweight from Equal Weight at Wells Fargo
Nov 11, 2026, 4:03 PM EST · 1 day ago enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
Nov 11, 2026, 4:01 PM EST · 1 day ago enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones
Sep 8, 2026, 7:30 AM EDT · 2 months ago enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
Aug 4, 2026, 8:00 AM EDT · 3 months ago enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
2026-07-16T12:12:12.000Z · 3 months ago enGene announces changes to board, appoints Heffernan as Chairman
Jul 16, 2026, 8:00 AM EDT · 3 months ago enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Jul 15, 2026, 9:00 AM EDT · 4 months ago Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman GERN
2026-06-18T10:00:10.000Z · 4 months ago enGene downgraded to Underweight from Equal Weight at Morgan Stanley
Jun 15, 2026, 9:00 AM EDT · 5 months ago enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-05-08T18:32:38.000Z · 6 months ago Leerink downgraded enGene to Market Perform following LEGEND update
2026-05-08T12:11:57.000Z · 6 months ago enGene downgraded to Market Perform from Outperform at Leerink
2026-05-08T09:16:27.000Z · 6 months ago enGene downgraded to Outperform from Strong Buy at Raymond James
May 7, 2026, 3:35 PM EDT · 6 months ago enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
May 7, 2026, 7:00 AM EDT · 6 months ago enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
Mar 9, 2026, 7:00 AM EDT · 8 months ago enGene Reports First Quarter 2026 Financial Results and Provides Business Update
Feb 4, 2026, 8:00 AM EST · 9 months ago enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Jan 20, 2026, 5:35 PM EST · 9 months ago enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc. HTGC
Dec 22, 2025, 4:03 PM EST · 10 months ago enGene Reports Full Year 2025 Financial Results and Provides Business Update
Dec 2, 2025, 7:30 AM EST · 11 months ago enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
Nov 25, 2025, 7:30 AM EST · 11 months ago enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
Nov 13, 2025, 12:27 AM EST · 12 months ago enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
Nov 11, 2025, 7:30 AM EST · 1 year ago Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
Nov 10, 2025, 4:05 PM EST · 1 year ago enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
Oct 1, 2025, 4:03 PM EDT · 1 year ago enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 30, 2025, 7:30 AM EDT · 1 year ago enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
Sep 11, 2025, 4:03 PM EDT · 1 year ago enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
Sep 3, 2025, 7:30 AM EDT · 1 year ago enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort
Jul 8, 2025, 8:00 AM EDT · 1 year ago enGene Announces Board and Leadership Appointments to Support Commercial Readiness
Jun 25, 2025, 8:00 AM EDT · 1 year ago FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
Jun 12, 2025, 8:00 AM EDT · 1 year ago enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
May 29, 2025, 8:00 AM EDT · 1 year ago enGene to Present at the Jefferies Global Healthcare Conference
May 28, 2025, 7:30 AM EDT · 1 year ago enGene Names Amy Pott as Chief Global Commercialization Officer
Apr 1, 2025, 8:00 AM EDT · 1 year ago enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
Mar 10, 2025, 4:05 PM EDT · 1 year ago enGene Reports First Quarter 2025 Financial Results and Provides Business Update
Mar 4, 2025, 8:00 AM EST · 1 year ago enGene to Participate in the Leerink Partners Global Healthcare Conference
Feb 4, 2025, 8:00 AM EST · 1 year ago enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Jan 30, 2025, 8:00 AM EST · 1 year ago enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
Dec 19, 2024, 4:05 PM EST · 1 year ago enGene Reports Full Year 2024 Financial Results and Provides a Business Update
Nov 5, 2024, 8:00 AM EST · 2 years ago enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Oct 22, 2024, 4:05 PM EDT · 2 years ago enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Oct 21, 2024, 8:45 AM EDT · 2 years ago enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
Sep 26, 2024, 6:30 AM EDT · 2 years ago Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
Sep 10, 2024, 4:33 PM EDT · 2 years ago enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
Jul 24, 2024, 4:05 PM EDT · 2 years ago enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Jul 24, 2024, 6:30 AM EDT · 2 years ago enGene Announces Appointment of Ron Cooper as Chief Executive Officer
Jun 14, 2024, 7:01 AM EDT · 2 years ago enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update